图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm Therapeutics(KPTI)$ 内部交易: 2016-05-20,10% Owner,Chione Ltd ,卖出,40000普通股, $8.52
$Karyopharm Therapeutics(KPTI)$ 内部交易: 2016-05-19,10% Owner,Chione Ltd ,卖出,20000普通股, $8.18
$Karyopharm Therapeutics(KPTI)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2016-05-19 AccNo: 0001193125-16-596160 Size: 475 KB 网页链接
$Karyopharm Therapeutics(KPTI)$ EFFECT - Notice of Effectiveness Filed: 2016-05-17 AccNo: 9999999995-16-004685 Size: 1 KB 网页链接
$Karyopharm Therapeutics(KPTI)$ POS AM - Post-Effective amendments for registration statement Filed: 2016-05-17 AccNo: 0001193125-16-593189 Size: 279 KB 网页链接
$Karyopharm Therapeutics(KPTI)$ 内部交易: 2016-05-11,10% Owner,Chione Ltd ,卖出,11868普通股, $8.41
$Karyopharm Therapeutics(KPTI)$ 内部交易: 2016-05-10,10% Owner,Chione Ltd ,卖出,20000普通股, $8.14
$Karyopharm Therapeutics(KPTI)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2016-05-09 AccNo: 0000038777-16-000517 Size: 211 KB 网页链接
$Karyopharm Therapeutics(KPTI)$ 8-K - Current report Filed: 2016-05-09 AccNo: 0001193125-16-582769 Size: 88 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Karyopharm Therapeutics(KPTI)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2016-05-09 AccNo: 0001193125-16-583808 Size: 2 MB 网页链接